The off-label use of the dangerous cancer drug Avastin for macular degeneration appears to be based on one study, which showed Avastin worked just as well as Lucentis—a licensed but more expensive eye drug. Meanwhile, numerous studies exist demonstrating the treatment potential of astaxanthin for this eye
Read more →
